Biotronik

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Biotronik sits in the top decile of US sponsors by registered trial count (#538 of 15,742 sponsors by registered trial count).

30 total trials 1 currently recruiting 20 completed top decile by trial count

Biotronik: 30 sponsored US clinical trials, 1 recruiting.

Biotronik sponsors 30 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 20 completed. 5 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Bradycardia, with 2 trials.

Top-decile sponsor footprint

Biotronik ranks in the top decile of sponsors by registered trial count (#538 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 18/100

20 of 28 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (71.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

30 total, page 1 of 1

RECRUITING NA

BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System

NCT07118358

ACTIVE NOT RECRUITING NA

BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S

NCT06540079

COMPLETED NA

BIOTRONIK Conduction System Pacing With the Solia Lead

NCT05251363

TERMINATED

Atrial Fibrillation Associated With Heart Failure Treated by BIOTRONIK's CRT-DX System

NCT04870281

COMPLETED

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

NCT04175626

TERMINATED

Assessment of the Utility of BIOMONITOR to Identify Atrial Fibrillation (AF) in Ablation Candidates Using Precise AF Detection

NCT04076917

COMPLETED

Analysis of Both Sex and Device Specific Factors on Outcomes in Patients with Non-Ischemic Cardiomyopathy

NCT03884608

COMPLETED NA

Comparison of the Effects of Two Spinal Cord Stimulation (SCS) Therapies on Subject Reported Pain (BENEFIT-02)

NCT03594266

COMPLETED NA

QP ExCELs: MultiPole Pacing (MPP) Sub-Study

NCT03155724

TERMINATED

Plexa ICD Lead Registry

NCT03103503

COMPLETED

BioMonitor 2 In-Office Setting Insertion Safety and Feasibility Evaluation With Device Functionality Assessment

NCT02756338

COMPLETED NA

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

NCT02389946

TERMINATED

Protego DF4 Post Approval Registry

NCT02243696

COMPLETED

ProMRI Study of the Iforia ICD System (Phase C)

NCT02096692

COMPLETED

ProMRI Study of the Entovis Pacemaker System (Phase B)

NCT02009696

TERMINATED

Safety and Performance Study of the Siello S Pacing Lead

NCT01791127

COMPLETED

ProMRI Study of the Entovis Pacemaker System

NCT01761162

COMPLETED Phase 2

BIOHELIX-I Bare Metal Stent Study

NCT01612767

COMPLETED Phase 2

Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents

NCT01319812

COMPLETED

Long-term Evaluation of the Linox Family ICD Leads Registry (GALAXY)

NCT00836589

COMPLETED

Post Approval Registry of Corox OTW, Endocardial, Left Ventricular Steroid Lead, Bipolar

NCT00810264

TERMINATED Phase 2

Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)

NCT00683696

TERMINATED Phase 4

Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk

NCT00559988

COMPLETED

REPLACE: Implantable Cardiac Pulse Generator Replacement Registry

NCT00395447

COMPLETED Phase 2

Interventricular Delay of Lumax HF-T for Heart Failure

NCT00508391

COMPLETED Phase 4

TRIAGE-CRT Telemonitoring in Patients With CHF and Indication of CRT-D

NCT00395642

COMPLETED Phase 4

COSMO Post Approval Registry: Corox OTW Steroid LV Lead Monitoring

NCT00396136

COMPLETED Phase 4

Effectiveness of Pacemaker With Closed Loop Stimulation Compared to Pacemakers With and Without Standard Rate Response

NCT00355797

COMPLETED Phase 4

TRUST: Lumos-T Safely RedUceS RouTine Office Device Follow-up

NCT00336284

TERMINATED NA

Investigational Device Exemption (IDE) Study for the Approval of Closed Loop Stimulation (CLS) and Cardiac Resyncronization Pacing Therapies (CRT) for the Treatment of Atrial Fibrillation (AF) With Ablate and Pace

NCT00356057

What is open in the Biotronik pipeline

1 recruiting of 30 indexed (3% open); 20 completed (67%).

Phase mix: 5 late (III/IV) vs 4 early (I/II) (balanced across stages).

Top condition: Bradycardia (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Biotronik: open-pipeline peers nationwide

Peers matched on 30 registered trials and 3% open enrollment, not the therapeutic-area sidebar.

Biotronik sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400 0%5%10%15%20% Total trials Recruiting share BiotronikCharles Drew University of Medicine and ScienceChiesi Farmaceutici S.p.A.Debiopharm InternationalExact Sciences CorporationKyntra BioNew York State Psychiatric InstituteWills EyeSCRI Development Innovations
Biotronik sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Biotronik sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 30 trials (± recruiting share)

Sponsors near 3% open enrollment (± trial volume)

What to do with this Biotronik page

30 registered trials is a research-attention snapshot, not an endorsement of Biotronik or any single study.

  • 1 of Biotronik's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Bradycardia is the condition Biotronik studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Bradycardia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Biotronik pipeline card: 30 registered trials from official public datasets.Report a data error.